全球未分級肝素市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2034 年，未分級肝素市場規模將從 2025 年的 13.4 億美元成長至 24.1 億美元，2026 年至 2034 年的複合年成長率為 6.68%。

由於未分級肝素在抗凝血治療中發揮至關重要的作用，且臨床應用廣泛，預計其全球市場將穩步成長。儘管低分子量肝素製劑的應用日益增多，但未分級肝素在心血管手術、透析和體外循環中仍然不可或缺。其起效迅速且作用可逆，使其成為首選藥物，尤其是在加護病房(ICU) 等需要病患病情穩定的急診醫療環境中。隨著新興經濟體醫療基礎設施的不斷完善，對經濟有效的抗凝血劑的需求預計將保持強勁，從而推動市場成長。

肝素萃取和純化技術的進步正在提高產品品質和安全性，最大限度地減少肝素誘發的血小板減少性疾病不利事件。此外，對合成和重組生產過程的持續研究有望減少對豬源性原料的依賴，並解決供應鏈脆弱性和倫理問題。這些創新可望在確保符合嚴格監管要求的同時，樹立生產效率的新標準。這些進展不僅將增強供應穩定性，還將為高品質肝素製劑開闢新的機會。

該市場的未來趨勢將受到全球心血管疾病和血栓性栓塞症負擔日益加重的顯著影響。此外，外科手術和透析治療數量的不斷成長也凸顯了對可靠抗凝血劑的持續需求。市場參與企業正積極投資於後向整合、合作研究和地理擴張，以保持其長期競爭力。加之政府對改善基本藥物可近性的支持，預計未分級肝素將繼續在挽救生命的治療通訊協定中發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球未分級肝素市場：依來源分類

• 市場分析、洞察與預測
• 源自牛
• 源自豬

第5章：全球未分級肝素市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第6章 全球未分級肝素市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Becton
  • Dickinson And Company
  • BioMAfA（C）Rieux SA
  • Bio-Rad Laboratories Inc
  • Eiken Chemical Co. Ltd
  • Merck Millipore（EMD Millipore）
  • HiMedia Laboratories Pvt. Ltd
  • Neogen Corporation
  • Sigma-Aldrich Co. LLC
  • Scharlab SL
  • Thermo Fisher Scientific Inc

The Unfractionated Heparin Market size is expected to reach USD 2.41 Billion in 2034 from USD 1.34 Billion (2025) growing at a CAGR of 6.68% during 2026-2034.

The global unfractionated heparin market is poised for steady growth, driven by its critical role in anticoagulation therapy and broad clinical applications. Despite the rising adoption of low-molecular-weight alternatives, unfractionated heparin continues to be indispensable in cardiovascular surgeries, dialysis procedures, and extracorporeal circulation. Its rapid onset of action and reversibility make it a preferred choice in acute care environments, particularly in intensive care units where patient stability is paramount. With expanding healthcare infrastructure across emerging economies, the demand for cost-effective anticoagulants is expected to remain resilient, supporting market expansion.

Technological advancements in heparin extraction and purification methods are enhancing product quality and safety, thereby minimizing adverse events such as heparin-induced thrombocytopenia. Moreover, ongoing research into synthetic and recombinant production processes could reduce dependency on porcine sources, addressing both supply chain vulnerabilities and ethical concerns. These innovations are likely to establish new benchmarks in production efficiency while ensuring compliance with stringent regulatory standards. Such developments not only strengthen supply security but also open new opportunities for premium-grade heparin formulations.

The future trajectory of this market will be strongly influenced by the rising global burden of cardiovascular and thromboembolic disorders. Additionally, the increasing volume of surgical procedures and dialysis sessions underscores the persistent need for reliable anticoagulants. Market participants are strategically investing in backward integration, collaborative research, and geographical expansion to sustain long-term competitiveness. With supportive government initiatives to improve accessibility to essential medicines, unfractionated heparin is expected to remain a cornerstone in life-saving therapeutic protocols.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source

• Bovine
• Porcine

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Becton, Dickinson and Company, bioMrieux SA, BioRad Laboratories Inc, Eiken Chemical Co Ltd, Merck Millipore EMD Millipore, HiMedia Laboratories Pvt Ltd, Neogen Corporation, SigmaAldrich Co LLC, Scharlab SL, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL UNFRACTIONATED HEPARIN MARKET: BY SOURCE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Source
• 4.2. Bovine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Porcine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL UNFRACTIONATED HEPARIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL UNFRACTIONATED HEPARIN MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Source
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Source
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Source
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Source
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Source
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL UNFRACTIONATED HEPARIN INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Becton
  • 8.2.2 Dickinson And Company
  • 8.2.3 BioMAfA(C)Rieux S.A
  • 8.2.4 Bio-Rad Laboratories Inc
  • 8.2.5 Eiken Chemical Co. Ltd
  • 8.2.6 Merck Millipore (EMD Millipore)
  • 8.2.7 HiMedia Laboratories Pvt. Ltd
  • 8.2.8 Neogen Corporation
  • 8.2.9 Sigma-Aldrich Co. LLC
  • 8.2.10 Scharlab S.L
  • 8.2.11 Thermo Fisher Scientific Inc